Stifel Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $803K | Sell |
22,081
-1,298
| -6% | -$47.2K | ﹤0.01% | 2479 |
|
|
2025
Q1 | $847K | Sell |
23,379
-417
| -2% | -$15.1K | ﹤0.01% | 2341 |
|
|
2024
Q4 | $1M | Buy |
23,796
+2,835
| +14% | +$119K | ﹤0.01% | 2236 |
|
|
2024
Q3 | $1.16M | Sell |
20,961
-866
| -4% | -$48.1K | ﹤0.01% | 2128 |
|
|
2024
Q2 | $897K | Buy |
21,827
+8,461
| +63% | +$348K | ﹤0.01% | 2237 |
|
|
2024
Q1 | $624K | Buy |
13,366
+872
| +7% | +$40.7K | ﹤0.01% | 2478 |
|
|
2023
Q4 | $597K | Buy |
12,494
+2,654
| +27% | +$127K | ﹤0.01% | 2472 |
|
|
2023
Q3 | $351K | Buy |
9,840
+4,343
| +79% | +$155K | ﹤0.01% | 2696 |
|
|
2023
Q2 | $254K | Buy |
+5,497
| New | +$254K | ﹤0.01% | 2927 |
|
|
2022
Q3 | – | Sell |
-3,905
| Closed | -$233K | – | 3366 |
|
|
2022
Q2 | $233K | Buy |
3,905
+37
| +1% | +$2.21K | ﹤0.01% | 2892 |
|
|
2022
Q1 | $281K | Buy |
3,868
+610
| +19% | +$44.3K | ﹤0.01% | 2912 |
|
|
2021
Q4 | $274K | Sell |
3,258
-100
| -3% | -$8.41K | ﹤0.01% | 2968 |
|
|
2021
Q3 | $303K | Buy |
3,358
+331
| +11% | +$29.9K | ﹤0.01% | 2899 |
|
|
2021
Q2 | $289K | Sell |
3,027
-589
| -16% | -$56.2K | ﹤0.01% | 2921 |
|
|
2021
Q1 | $412K | Sell |
3,616
-125
| -3% | -$14.2K | ﹤0.01% | 2598 |
|
|
2020
Q4 | $518K | Buy |
3,741
+700
| +23% | +$96.9K | ﹤0.01% | 2296 |
|
|
2020
Q3 | $250K | Sell |
3,041
-194
| -6% | -$15.9K | ﹤0.01% | 2501 |
|
|
2020
Q2 | $253K | Sell |
3,235
-1,550
| -32% | -$121K | ﹤0.01% | 2467 |
|
|
2020
Q1 | $213K | Buy |
+4,785
| New | +$213K | ﹤0.01% | 2402 |
|
|
2019
Q2 | – | Sell |
-11,327
| Closed | -$786K | – | 3029 |
|
|
2019
Q1 | $786K | Buy |
+11,327
| New | +$786K | ﹤0.01% | 1804 |
|
|
2015
Q3 | – | Sell |
-19,241
| Closed | -$1.97M | – | 2343 |
|
|
2015
Q2 | $1.97M | Buy |
+19,241
| New | +$1.97M | 0.01% | 1006 |
|